Lupus Erythematosus, Systemic Clinical Trial
— STOPSLEOfficial title:
Sirolimus Treatment of Patients With Systemic Lupus Erythematosus
Verified date | June 2023 |
Source | State University of New York - Upstate Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phase II Double-blind, placebo-controlled, randomized treatment trial with two arms: one SIROLIMUS arm with 92 patients and one placebo arm with 92 patients. The safety and therapeutic efficacy of SIROLIMUS will be determined within a dosage range of 1 mg/day to 4 mg/day, which will be titrated to tolerance during an initial 3-month open label period, relative to placebo in SLE patients over 12 months followed by a 1-month washout. The proposed study design, known as an enriched enrollment randomized withdrawal (EERW), has major advantages that (1) only people who tolerate SIROLIMUS are randomized, potentially reducing the percentage of dropouts in the randomized phase and (2) it allows participants to use an individualized dosage of study medication, which mimics clinical practice in terms of how SIROLIMUS would be administered. Healthy subjects receive no drugs and serve as controls for in vitro studies.
Status | Not yet recruiting |
Enrollment | 220 |
Est. completion date | January 1, 2029 |
Est. primary completion date | January 1, 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age > 18; 2. Male or female; 3. = 4 ACR SLE classification criteria; 4. Positive ANA at a titer of = 1/80; 5. Stable immunosuppressants (MMF = 3 g/day, azathioprine = 100 mg/day; methotrexate = 15 mg/day) and/or antimalarials (hydroxychloroquine = 400 mg/day) for 30 days prior to screening; stable oral corticosteroids for 2 weeks prior to screening; = 20 mg/day prednisone or equivalent; stable belimumab for 90 days prior to screening; 6. BILAG 2004 index (3) level A disease activity in = 1 organ/system except renal or central nervous system or (ii) BILAG 2004 index level B disease activity in = 2 organs/systems if no level A disease activity is present and (iii) SLEDAI = 6; 7. Enrollment is approved by adjudication committee. Exclusion Criteria: 1. Acute SLE flare threatening vital organs; 2. Pregnant or lactating; 3. Female subjects who are planning to become pregnant during the study or within 3 months after last dosing or male subjects who are considering fathering a child within 3 months after last dosing; 4. Abnormal laboratory test results: hemoglobin = 8 g/L (8 g/dL), platelet count = 70 x 109/L (70,000 cells/mm³), white blood cell count = 2.0 x 109/L (2,000 cells/mm³), neutrophils: = 1.5 X 109/L, proteinuria > 3 g/day measured by 24 hour collection or spot urine protein to creatinine ratio of >3; 5. Glomerular filtration rate (GFR) < 50 mL/min/1.73 m², any other clinically significant abnormal screening laboratory results as evaluated by the Investigator; 6. Moderately serious or serious comorbidities (e.g., diabetes mellitus, congestive heart failure, chronic obstructive pulmonary disease, chronic renal insufficiency) that in investigator's opinion confers high risk for adverse events; 7. Patients receiving cyclophosphamide within 3 months; 8. Active chronic infections (e.g., HIV, hepatitis B virus, hepatitis C virus, mycobacteria); patients with oral steroid-dependent asthma; 9. Infections requiring intravenous antibiotics within a month or oral antibiotics within two weeks of screening; 10. Patients taking (unwilling or unable to stop) NAC or other antioxidants within 1 month of screening (which is considered sufficient time to revert GSH to pre-treatment levels; 11. Patients receiving rituximab within 12 months or other biologic therapy within five half lives; 12. Patients receiving mTOR inhibitors (rapamycin/sirolimus, everolimus); 13. Patients enrolled in other interventional trials. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
State University of New York - Upstate Medical University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Therapeutic Benefit | Positive Response on SLE Responder Index (SRI) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|